Interactions between the cytochrome P450 system and the second-generation antipsychotics

Journal of Psychiatry and Neuroscience

Volumn 28, Issue 2, 2003, Pages 99-112

  Prior, Trevor I ^a,b   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA HOSPITAL EDMONTON   (Canada)

Author keywords

Antipsychotic agents; Biotransformation; Cytochrome P 450 enzyme system; Drug interactions; Metabolism; Schizophrenia

Indexed keywords

CAFFEINE; CARBAMAZEPINE; CIPROFLOXACIN; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUVOXAMINE; ISONIAZID; ITRACONAZOLE; NEFAZODONE; NEUROLEPTIC AGENT; NORCLOZAPINE; NORTRIPTYLINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; PYRAZINAMIDE; QUETIAPINE; QUINOLONE DERIVATIVE; RIFAMPICIN; RISPERIDONE; SERTRALINE; ZIPRASIDONE;

DOSE RESPONSE; DRUG CROSS REACTIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME KINETICS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PARKINSONISM; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LIVER; PSYCHOTIC DISORDERS;

EID: 0037679084     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Kessler RC, McGonagle KA, Zhao S. Lifetime 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
2. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Suppl):1-63.
3. Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998;43(Suppl 2):25S-40S.
4. Shen WW. The metabolism of atypical antipsychotic drugs: an update. Ann Clin Psychiatry 1999;11:145-58.
5. Parkinson A. Biotransformation of xenobiotics. In: Klaassen CD, editor. Casarett and Doull's toxicology: the basic science of poisons. 5th ed. New York: McGraw-Hill; 1996. p. 113-86.
6. Coutts RT, Fang J, Bourin M, Baker GB. Principles of drug metabolism, with an emphasis on psychiatric drugs. In: Boulton AA, Baker GB, Bateson AN, editors. Neuromethods. Vol. 33. Totowa (NJ): Humana Press; 1999. p. 255-86.
7. Ring BJ, Wrighton SA. Industrial viewpoint: application of in vitro drug metabolism in various phases of drug development. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Baltimore (MD): Lippincott, Williams and Wilkins; 2000. p. 29-39.
8. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Pharmacokinetics. In: Principles and practice of psychopharmacotherapy. 3rd ed. Baltimore (MD): Lippincott, Williams & Wilkins; 2001. p. 51-72.
9. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Pharmacokinetics, pharmacodynamics and drug disposition. In: Davis KL, Charney D, Coyle JL, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Baltimore (MD): Lippincott, Williams and Wilkins; 2002. p. 507-24.
10. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26:144-60.
11. Nelson DR, Kaymans L, Kamataki T, Stegeman JJ, Feyereison R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
12. Nelson DR. Cytochrome P450 and individuality of species. Arch Biochem Biophys 1999;369:1-10.
13. Glue P, Clement RP. Cytochrome P450 enzymes: in vitro assessment and clinical implications. In: Boulton AA, Baker GB, Bateson AN, editors. Neuromethods. Vol. 34. Totowa (NJ): Humana Press; 1998. p. 195-211.
14. Aitchison KJ, Jordan BD, Sharon T. The relevance of ethnic influences of pharmacogenetics to the treatment of psychosis. Drug Metabol Drug Interact 2000;16:15-38.
15. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000;25:197-220.
16. Meisel C, Roots I, Cascorbi I, Brinkmann U, Brockmoller J. How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med 2000;38:869-76.
17. Hiratsuka M, Mizugaki M. Genetic polymorphisms in drug-metabolising enzymes and drug targets. Mol Genet Metab 2001;73:298-305.
18. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90.
19. Lin JH, Lu AYH. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001;41:535-67.
20. Ronis MJJ, Ingelmann-Sundberg M. Induction of human drug-metabolizing enzymes: mechanisms and implications. In: Wolff TE, editor. Handbook of drug metabolism. New York: Marcel Dekker; 1999. p. 239-62.
21. Shen WW. The metabolism of psychotic drugs: a review of enzymatic biotransformation and inhibition. Biol Psychiatry 1997;41:814-26.
22. Kern A, Bader A, Pichlmayr R, Sewing KF. Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem Pharmacol 1997;54:761-72.
23. Guillouzo A. Liver cell models in in vitro toxicology. Environ Health Perspect 1998;106:511-32.
24. Glue P, Banfield C. Psychiatry, psychopharmacology and P-450s. Hum Psychopharmacol 1996;11:97-114.
25. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Ohiba K, et al. Predictions of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997;73:147-51.
26. Bertz RJ, Grannerman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
27. Wright SA, Ring BJ. Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience. Drug Metab Rev 1999;31:15-28.
28. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001;13:343-68.
29. Lane RM. Pharmacokinetic drug interaction potential of selective-serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996;11:31-61.
30. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of the literature. J Clin Psychopharmacol 1996;16:177-87.
31. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997;171:109-12.
32. Fang J, Coutts RT, McKenna KF, Baker GB. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn-Schmiedebergs Arch Pharmacol 1998;358:592-9.
33. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984-90.
34. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44:439-46.
35. Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997;25:1379-82.
36. Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001;41:823-32.
37. Tugnait M, Hawes EM, McKay G, Eichelbaum M, Midha KK Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem Biol Interact 1999;118:171-89.
38. Brosen K. The pharmacogenetics of the selective serotonin re-uptake inhibitors. Clin Investig 1993;71:1002-9.
39. Jeppessen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxefine. Eur J Clin Pharmacol 1996;51:73-8.
40. Jeppesen U, Rasmussen BB, Brosen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997;62:279-86.
41. Chang WH, Augustin B, Lane HY, ZumBrunnen T, Liu HC, Kazmi Y, et al. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology 1999;145:91-8.
42. Olesen OV, Linnet K. Fluvoxamme-clozapine drug interaction inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000;20:35-42.
43. Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, et al. Clozapine disposition covaries with CYP1A2 activity determined by the caffeine test. Br J Clin Pharmacol 1994;38:471-3.
44. Bender S, Eap CB. Very high cytochrome P450 1A2 activity and non-response to clozapine. Arch Gen Psychiatry 1998;55:1048-50.
45. Jerling M, Merle Y, Mentrè F, Mallet A. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1997;44:447-53.
46. Vanier JL, Chouinard G. Interaction between caffeine and clozapine. J Clin Psychopharmacol 1994;14:284-5.
47. Odom-White JA, de Leon J. Clozapine levels and coffee. J Clin Psychiatry 1996;57:175-6.
48. Carrillo JA, Herraiz AG, Ramos SI, Benítez MD. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 1998;18:311-6.
49. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2000;15:469-94.
50. Haring C, Meise U, Humpel C, Saria A, Fleischacker WW, Hinterhuber H. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl) 1989;99(Suppl):S38-40.
51. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Hartter S, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2-9.
52. Seppala NH, Leinonen EVJ, Lehtonen ML, Kivistö KT. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 1999;85,244-6.
53. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993;13:383-90.
54. McCarthy R. Seizure following smoking cessation in a clozapine responder. Pharmacopsychiatry 1994;27:210-1.
55. Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther Drug Monit 1999;21:580-2.
56. Weigmann H, Muller H, Dahmer W, Wetzel H, Hiemke C. Interaction of fluvoxamine with the metabolism of clozapine. Pharmacopsychiatry 1993;26:209.
57. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Muller H. Elevated level of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
58. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
59. Szegedi A, Weisner J, Hiemke C. Improved efficacy and fewer side effects under clozapine therapy after addition of fluvoxamine. J Clin Psychopharmacol 1995;15:141-3.
60. Dequardo JR, Roberts M. Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 1996;153:840-1.
61. DuMartier G, Lochu A, Colon de Melo CP, Ghribi O, Roche-Rabreau D, DeGrassat K, et al. Elevated clozapine plasma concentrations after fluvoxamine initiation. Am J Psychiatry 1996;153:738-9.
62. Koponen HJ, Leinonen E, Lepola U. Fluvoxamine increases the serum clozapine levels significantly. Eur Neuropsychopharmacol 1996;6:69-71.
63. Armstrong SC, Stephans JR. Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage. J Clin Psychiatry 1997;58:499.
64. Heeringa M, Beurskens R, Schouten W, Verduijn MM. Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 1999;21:243-4.
65. Lammers CH, Deuschle M, Weigmann H, Härtter S, Hiemke C, Heese C, et al. Coadministration of clozapine and fluvoxamine in psychotic patients - clinical experience. Pharmacopsychiatry 1999;32:76-7.
66. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH. Fluvoxamine reduces clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000;61:594-9.
67. Joos AAB, Frank UG, Kaschka WP. Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection. J Clin Psychopharmacol 1998;18:83-5.
68. Wietholtz H, Zysset T, Marschall HU, Generet K, Matern S. The influence of rifampin treatment on caffeine clearance in healthy man. J Hepatol 1995;22:78-81.
69. Baciewicz AM, Self TH. Isoniazid interactions. South Med J 1985;78:714-8.
70. Batty KY, Davis TM, Ilett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995;39:305-11.
71. Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P450 1A2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992;36:942-8.
72. Markowitz JS, Gill HS, Devane CL, Mintzer JE. Fluoroquinolone inhibition of clozapine metabolism. Am J Psychiatry 1997;154:881.
73. Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 2000;56:585-9.
74. Eggert AC, Crismon ML, Dovjon PG. Lack of effect of fluoxetine on plasma clozapine concentration. J Clin Psychiatry 1994;55:454-5.
75. Joos AAB, König F, Frank UG, Kaschka WP, Mörike KE, Ewald R. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. Pharmacopsychiatry 1997;30:266-70.
76. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820-2.
77. Centorrino F, Baldessarini RJ, Kando J, Frankenburg F, Volpicelli SA, Puopolo PR, et al. Serum concentration of clozapine and its major metabolite: effect with fluoxetine and valproate. Am J Psychiatry 1994;151:123-5.
78. Spina E, Avenoso A, Facciolá G, Fabrazzo M, Mateleone P, Maj M, et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998;13:141-5.
79. Tyson SC, Devane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995;152:1401-2.
80. Koreen AR, Lieberman JA, Kronig M, Cooper TB. Cross-tapering clozapine and risperidone. Am J Psychiatry 1995;152:1690.
81. Dahl ML, Llerena A, Bondesson U, Lindström L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Pharmacol 1994;37:71-4.
82. Arranz MJ, Dawson E, Shaikh S, Sham P, Sharma T, Aitchison K, et al. Cytochrome P450 2D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 1995;39:417-20.
83. Murray M. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992;23:132-46.
84. Funderburg L, Vertrees J, True J, Miller A. Seizure following addition of erythromycin to clozapine therapy. Am J Psychiatry 1994;151:1840-1.
85. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reaction. Arch Intern Med 1996;156:675-7.
86. Hägg S, Spigset O, Mjörndal T, Granberg K, Persbo-Lundqvist G, Dahlqvist R. Absence of interaction between erythromycin and a single dose of clozapine. Eur J Clin Pharmacol 1999;55:221-6.
87. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, et al. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacologia 1999;145:113-22.
88. Khan AY, Preskorn SH. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. J Clin Psychiatry 2001;62:375-6.
89. Taylor D, Bodani M, Hubbeling A, Murray R. The effect of nefazodone on clozapine plasma concentrations. Int Clin Psychopharmacol 1999;14:185-7.
90. Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 1998;54:167-70.
91. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996;41:181-6.
92. Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 1999;27:1078-84.
93. Smith T, Risken J. Effect of clozapine on plasma nortriptyline concentration. Pharmacopsychiatry 1994;27:41-2.
94. Hedlund E, Wyas A, Kainu T, Backlund M, Köhler C, Pelto-Huikko M, et al. Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene. Mol Pharmacol 1996;50:342-50.
95. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000;38:393-414.
96. Lavrijsen K, Meuldermans W, Heykants J. In vitro inhibition study in human liver microsomes to investigate the interaction potential of various drugs with the metabolism of risperidone. Janssen Preclinical Research Report R64 776/FK1257. Bruges, Belgium: Janssen; 1993.
97. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4. Naunyn-Schmiedebergs Arch Pharmacol 1999;359:147-51.
98. Mannens G, Huang ML, Meuldermanns W, Hendricks J, Woestenborghs R, Heykants J. Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos 1993;21:1134-41.
99. Huang ML, van Peer A, Woestenborghs R, DeCoster R, Heykants J, Jansen AAJ, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:251-68.
100. Olesen OV, Licht RW, Thomsen E, Bruun T, Viffrup JE, Linnet K. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998;20:380-4.
101. Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 1999;147:300-5.
102. Bork JA, Rogers T, Wedlund PJ, de Leon J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999;60:469-76.
103. Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia A. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 2001;23:223-7.
104. Leonard BE. An introduction to enantiomers in psychopharmacology. Hum Psychopharmacol 2001;16:S79-S84.
105. Baker GB, Prior TI. Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs. Ann Med 2002;34:537-43.
106. Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001;29:1263-8.
107. de Leon J, Bork J. Risperidone and cytochrome P450 3A. J Clin Psychiatry 1997;58:10.
108. Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Giacobello T, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000;22:481-5.
109. Spina E, Scordo MG, Avenoso A, Perucca E. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. J Clin Psychopharmacol 2001;21:108-9.
110. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000;49:35S-42S.
111. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-93.
112. Markowitz JS, Devane CL, Liston HL, Boulton DW, Risch SC. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clin Pharmacol Ther 2002;71:30-8.
113. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-66.
114. Mäenpää J, Wrighton S, Bergstrom R, Cerimele B, Tatum D, Hatcher B, et al. Pharmacokinetic and pharmacodynamic interactions between fluvoxamine and olanzapine. Clin Pharmacol Ther 1997;61:225.
115. Markowitz JS, DeVane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration. J Clin Psychopharmacol 1999;19:289-91.
116. Parker AC, Pritchard P, Preston T, Choonara I. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 1998;45:176-8.
117. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 1998;54:639-43.
118. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Metab 1999;21:87-90.
119. Macias WL, Bergstrom RF, Cerimele BJ, Kassahm K, Tatum DE, Callaghan JT. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy 1998;18:1237-48.
120. Dev V, Raniwalla J. Quetiapine: a review of its safety in the management of schizophrenia. Drug Safety 2000;23:296-307.
121. Goldstein JM. Quetiapine fumarate (Seroquel®): a new atypical antipsychotic. Drugs Today 1999;35:193-210.
122. Wong YWJ, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001;21:89-93.
123. Savasi I, Millson RC, Owen JA. Quetiapine blood level variability. Can J Psychiatry 2002;47:94.
124. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 2000;49:71S-76S.
125. Wilner KD, Demattos SB, Anziano RJ, Apseloff G, Gerber N. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol 2000;49:43S-47S.